6467370
Last Update Posted: 2025-02-07
Recruiting has ended
All Genders accepted | 18 Years + |
375 Estimated Participants | No Expanded Access |
Observational Study | Accepts healthy volunteers |
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects:
- Consistency of response to rimegepant across multiple attacks
- Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA
This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects:
- Consistency of response to rimegepant across multiple attacks
- Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA
Eligibility
Relevant conditions:
Migraine
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Data sourced from ClinicalTrials.gov